Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol., 08 January 2026

Sec. Molecular and Cellular Pathology

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1733128

This article is part of the Research TopicIntegrating Cutting-edge Technologies in Ophthalmology: From AI Breakthroughs to Cellular Research DiscoveriesView all 7 articles

Orally administered fluorescein angiography for ultra-wide-field imaging: is a safe and effective modality across different age groups and fundus diseases?

Yuke Ji&#x;Yuke Ji1Xinya Hu&#x;Xinya Hu2Yuting Hu&#x;Yuting Hu3Sisi LaiSisi Lai2Xiaofeng LuXiaofeng Lu2Xuan LiXuan Li2Zixiao LiuZixiao Liu2Shaochong Zhang,
Shaochong Zhang1,2*Weihua Yang
Weihua Yang2*Xue Yao
Xue Yao2*
  • 1Shenzhen Eye Hospital, Jinan University, Shenzhen, Guangdong, China
  • 2Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University Shenzhen, Shenzhen, Guangdong, China
  • 3Department of Ophthalmology and Optometry, Fujian Medical University, Fuzhou, Fujian, China

Purpose: To comprehensively evaluate the clinical utility, imaging performance, and safety of orally administered fluorescein angiography (oral FA) combined with an ultra-wide-field imaging system in the diagnosis and management of fundus disorders.

Methods: This prospective study enrolled 382 patients (676 eyes) aged 4–83 years, comprising 164 females and 218 males. All participants underwent oral FA after ingesting a weight-based dose of fluorescein sodium. Anonymized peak-phase images were independently graded by four retina specialists using a standardized three-parameter scoring system. Images were classified as high, moderate, or poor quality based on total scores. Circulation times (first appearance time, detailed visualization time, and optimal visualization time) and adverse events were systematically recorded. Statistical analyses assessed differences in image quality and timing across age groups and disease categories.

Results: Oral FA was successfully performed in all cases. Among 676 eyes, 662 (97.9%) were graded as high quality, 12 (1.8%) as moderate quality, and 2 (0.3%) as poor quality. Clinically useful images were obtained in 99.7% of cases. No significant differences in image quality or circulation times were observed across age groups. However, image quality was significantly higher in retinal degenerative diseases compared to retinal vascular diseases (P = 0.001), though both groups maintained diagnostically adequate scores. In addition, no significant differences in circulation times (first appearance time, detailed visualization time, and optimal visualization time) were observed among any disease groups. Mild adverse events (nausea, rash) occurred in only 2.1% of patients, with no severe reactions—even in six patients with prior intravenous FA (IVFA) allergy history.

Conclusion: Oral FA is a well-tolerated and clinically effective imaging modality that produces high-quality, diagnostically reliable angiograms across all age groups and multiple retinal disease categories. Its non-invasive nature, excellent safety profile, and ability to visualize peripheral pathology support its use as a practical and valuable alternative to conventional IVFA, particularly in pediatric, needle-phobic, or allergy-prone populations.

1 Introduction

Fundus diseases represent a leading cause of blindness worldwide (Li et al., 2023; He et al., 2023) The comprehensive evaluation of these conditions—encompassing retinal vascular diseases, chorioretinitis, retinal degenerative diseases, macular diseases, and optic nerve disorders—is crucial for accurate diagnosis, management, and monitoring of disease progression (Noh et al., 2023; Yu et al., 2025; Ji et al., 2023). Fluorescein angiography (FA) has been widely regarded as the gold standard imaging modality for assessing retinal and choroidal circulation (Ahmed et al., 2021; Hans et al., 2022). Conventional FA, which involves intravenous FA (IVFA), provides dynamic visualization of blood flow, vascular leakage, and pathological changes (Bulson and Faridi, 2017; Chen et al., 2022). However, IVFA is associated with potential side effects ranging from transient nausea and vomiting to rare but severe anaphylactic reactions (Ebrahimiadib et al., 2023; Hitosugi et al., 2004; Kornblau and El-Annan, 2019; Su et al., 2012). Furthermore, traditional FA has a limited field of view, typically capturing a limited area of the posterior pole, thereby missing peripheral retinal pathology that is critical in many retinal diseases (Temkar et al., 2019; Manivannan et al., 2005). Recent technological advancements have led to the development of ultra-wide-field (UWF) imaging systems, which have revolutionized retinal assessment. These systems enable comprehensive visualization of up to 200o field of the retina, including the far periphery, facilitating the detection of peripheral pathologies that were previously difficult to document (Lip et al., 2020; Tsui et al., 2013; Friberg et al., 2008). The integration of UWF imaging with FA has significantly enhanced our ability to evaluate a wide spectrum of retinal diseases.

Orally administered fluorescein angiography (oral FA) combined with ultra-wide-field imaging represents a significant innovation in retinal imaging. This technique involves oral administration of fluorescein dye followed by UWF imaging to provide detailed visualization of retinal vasculature and pathology (Marziali et al., 2022; Manoharan et al., 2017). Compared to conventional IVFA, oral FA offers several potential advantages: reduced risk of adverse reactions associated with intravenous injection, improved patient comfort and acceptance (particularly in pediatric populations and needle-phobic individuals), and the logistical simplicity of avoiding venipuncture. While the application of IVFA with UWF imaging for evaluating various fundus disorders has been well documented, studies focusing on oral FA remain limited. Previous studies have primarily explored this technique in pediatric populations (Elhusseiny et al., 2023; Marmoy et al., 2022), with few reports systematically evaluating its utility across a broad age spectrum or comparing its performance across different retinal disease categories. Furthermore, comprehensive assessments of image quality, circulation timing, and safety profiles of oral FA in diverse patient populations are lacking.

This study aims to systematically evaluate the clinical utility of oral FA by: 1) Assess whether oral FA provides diagnostic image quality comparable to that of IVFA across a broad spectrum of fundus diseases; 2) Evaluate its feasibility and performance across different disease categories and age groups; 3) Document the pharmacokinetic profile of oral FA, including circulation time and phase visualization; 4) Determine the safety of oral FA. By systematically analyzing these objectives, we seek to establish the clinical utility and limitations of oral FA and provide evidence for its potential role as a viable alternative to conventional IVFA in the management of ocular diseases.

2 Patients and methods

2.1 Patients ethics

The patients with various fundus diseases who received fluorescence vascular examination were enrolled consecutively in this study between March 2023 and June 2024 at Shenzhen Eye Hospital, China. This study follows the Helsinki Declaration and has been approved by the Medical Ethics Committee of the Shenzhen Ophthalmology Center (MR-44-23-002037). Oral FA involves the use of fluorescein sodium, and it is necessary to explain the potential risks and benefits to patients or their guardians to ensure informed decision-making. Therefore, we explained in detail the advantages and disadvantages of oral FA to the patients or their guardians and obtained informed consent (including parental/guardian consent for minors) from all participants.

2.2 Procedures

Using tropicamide (1%) to dilate the patient’s pupils before imaging, while loratadine and vitamin B6 were taken orally. Ultra-wide-field scanning laser ophthalmoscopy (Optos® California P200DTx, Optos plc, United Kingdom) was used for retinal angiograms of oral FA.

Previous studies have shown that the recommended dose of sodium fluorescein to generate an optimal oral angiogram was 20–30 mg/kg (Fung et al., 2014; Amram et al., 2018; Ali et al., 2018; Sugimoto et al., 2014). In this study, approximately 30 mg/kg of 20% fluorescein sodium (Xlateming®, Baiyunshan Mingxing, Guangzhou, China) was mixed with 10 mL of water and administered orally to each patient.

The imaging system timer was started once the patients had ingested the full dose of fluorescein sodium, as precise timing is critical to capture the optimal phases of fluorescence, ensuring high-quality imaging of the retinal vasculature. Images were taken every 1 s during the early arteriovenous phase and then every 5 min until the late phase was reached.

2.3 Definition of circulation times

The following key circulation time points were systematically recorded after oral fluorescein ingestion. The definitions were established prior to data analysis to ensure objectivity and reproducibility: 1) First appearance time: Defined as the time interval between oral intake and the first appearance of sodium fluorescein image on the optic disc. 2) Detailed visualization time: Defined as the time interval between oral intake and the visualization of retinal capillaries, macular arch or tertiary branch vessels. 3) Optimal visualization time: Defined as the time interval between oral intake and the frame exhibiting the peak fluorescence intensity of the entire fundus, resulting in the maximum contrast between the retinal vasculature and the background choroidal flush. All time points were determined by consensus between experienced graders who reviewed the entire angiographic sequence for each eye. Representative images of these key time points are shown in Figure 1.

Figure 1
Three-panel image showing retinal images labeled A, B, and C. A shows the first appearance of sodium fluorescein on the optic disc. B shows the visualization of retinal capillaries, macular arch or tertiary branch vessels. C displays the maximum contrast between the retinal vasculature and the background choroidal flush.

Figure 1. The representative images of different circulation time points. (A) The representative images of first appearance. (B) The representative images of detailed visualization. (C) The representative images of optimal visualization.

2.4 Image analysis

To quantitatively evaluate the utility of oral FA, the images were anonymized and randomized. Then, four experienced retinal specialists performed quality scoring, and all the scores were independently conducted. Only peak fluorescence filling phase images were provided for evaluation to reduce bias. Three parameters were used to score the images, modified from previously used methods (Amador-Patarroyo et al., 2020; Squirrell et al., 2005; Sawyer et al., 2024). The three parameters were: (Ⅰ) branch retinal vessel visualization, (Ⅱ) foveal avascular zone (FAZ) visualization, and (Ⅲ) clinically important findings, such as the presence of microaneurysms, neovascularization, leakage, visualization of nonperfusion areas, or macular edema. Three parameters score were as follows.

1. 0 points: first-order branches are seen; 1 point: second-order branches are seen; 2 points: third-order branches are seen.

2. 0 points: FAZ is impossible to judge; 1 point: FAZ is seen but not clearly; 2 points: FAZ is seen clearly.

3. 0 points: impossible to judge; 1 point: seen but not clearly; 2 points: seen clearly.

Representative images with scores for each of these parameters are shown in Figure 2. Representative images of different phases of oral FA are shown in Supplementary Figure S1.

Figure 2
Nine grayscale retinal images are shown in a grid. Rows are labeled (â… ), (â…¡), and (â…¢), with three columns labeled as 0 point, 1 point, and 2 points. Each image displays varying levels of vascular visibility and clarity, with increased brightness and contrast in the higher point columns, indicating different levels of retinal detail assessment.

Figure 2. Representative images of parameters I, II and III.

We used the sum of three parameter to evaluate image quality, which was modified from the methods previously used by Sayaka et al. (Yamao et al., 2021). The classification thresholds for image quality were established based on the consensus of all four retinal specialists, who independently determined the minimum scores required for clinical utility. Specifically, they agreed that parameter (I) must score 2 points (i.e., third-order branches visible), and parameters (II) and (III) must each score at least 1 point (i.e., FAZ and clinically important findings are discernible). These criteria correspond to a minimum total score of 4 points, which was defined as the threshold for clinically useful images. A total score of 5 or more points was considered high quality, as it indicates that at least one additional parameter achieved a higher score, further enhancing diagnostic confidence. Therefore, we classified the images into the following three grades to assess image quality: images with 5 points or more were defined as high quality. Clinically useful quality was required for a total score of 4 or more. Total scores between 4 and 5 points were considered moderate quality, and less than 4 points were considered poor quality.

2.5 Statistical analysis

Statistical analysis was performed using SPSS (version 27.0) and Prism 10 (GraphPad). The normality of data distribution was assessed using the Shapiro-Wilk test, and the homogeneity of variances was evaluated using Levene’s test. For comparisons among three or more groups, if the data met both assumptions of normality and homogeneity of variance, one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was applied. If the assumption of homogeneity of variance was violated, Welch’s ANOVA with Games-Howell post-hoc test was used. For comparisons between two independent groups, unpaired Student’s t-test or the Mann-Whitney U test was used based on the normality of the data. The Kruskal–Wallis test with Dunn’s post-hoc test was employed for multi-group comparisons when data were not normally distributed. Statistical significance was set at P < 0.05. Inter-observer reliability for the image quality scores was assessed using a two-way random-effects, absolute agreement, intraclass correlation coefficient (ICC).

3 Results

3.1 Patients characteristics

A total of 382 patients (676 eyes) aged between 4 and 83 years were recruited for this study, consisting of 164 women and 218 men. According to age, patients are divided into three age groups: 80 patients (20.9%) with 153 (22.6%) eyes were under 18 years old; 245 (64.1%) patients with 431 (63.8%) eyes were between 18 and 60 years old; and 57 (15.0%) patients with 92 (13.6%) eyes were over 60 years old. According to the pathology and location of fundus diseases, clinical diagnoses were divided into five categories: retinal vascular diseases (including central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy, familial exudative vitreoretinopathy, Coats’ disease, retinopathy of prematurity, and retinal vasculitis), chorioretinitis (including uveitis, choroiditis, and Vogt-Koyanagi-Harada Syndrome), retinal degenerative diseases (including retinitis pigmentosa, retinal detachment, and peripheral retinal degeneration), macular diseases (including central serous chorioretinopathy, age-related macular degeneration, central exudative chorioretinitis, epiretinal membrane, macular edema or hole, and retinoschisis), and optic nerve diseases (including anterior ischemic optic neuropathy, optic neuritis, and glaucoma). 131 (34.3%) patients with 220 (32.5%) eyes for retinal vascular diseases; 91 (23.8%) patients with 168 (24.9%) eyes for chorioretinitis; 75 (19.6%) patients with 146 (21.6%) eyes for retinal degenerative diseases; 59 (15.4%) patients with 93 (13.8%) eyes for macular diseases; and 26 (6.8%) patients with 49 (7.2%) eyes for optic nerve diseases. The characteristics of the patients in different groups are shown in Table 1.

Table 1
www.frontiersin.org

Table 1. Patients characters in different groups.

3.2 Image quality analysis

Image quality was assessed using three parameters. The final score for each image was calculated as the mean of the scores provided by the four independent retina specialists. The inter-observer reliability for the total image quality score was good. The ICC for single measures was 0.863 (95% CI: 0.847 - 0.889) for right eyes and 0.869 (95% CI: 0.841 - 0.884) for left eyes. Among the 382 cases (676 eyes) that underwent oral FA, 374 cases (662 eyes) were classified as high quality, 7 cases (12 eyes) as moderate quality, and 1 case (2 eyes) as low quality. Clinically useful images were obtained in 381 out of 382 cases (99.7%). One case of central retinal vein occlusion was classified as low quality due to vitreous hemorrhage obscuring the fundus. As shown in Table 2, the average image quality scores (AIQS) were 5.904 ± 0.326 in the under 18 years age group, 5.893 ± 0.415 in the 18–60 years group, and 5.796 ± 0.531 in the over 60 years group. When grouped by disease, the AIQS was 5.807 ± 0.565 for retinal vascular diseases, 5.881 ± 0.374 for chorioretinitis, 5.950 ± 0.243 for retinal degenerative diseases, 5.917 ± 0.348 for macular diseases, and 5.959 ± 0.164 for optic nerve diseases. No statistically significant differences were found among the different age groups (all P > 0.05). Among the disease categories, only retinal vascular diseases and retinal degenerative diseases show a statistically significant difference (P = 0.001, Figure 3).

Table 2
www.frontiersin.org

Table 2. AIQS of different groups.

Figure 3
Violin plots comparing average image quality scores. Panel A shows age groups: under 18, 18-60, and over 60 years. Panel B displays various eye conditions including retinal vascular diseases, chorioretinitis, retinal degenerative diseases, macular disease, and optic nerve diseases. P-values indicate statistical comparisons between groups.

Figure 3. The average image quality scores pairwise comparison of different groups. (A) The average image quality scores pairwise comparison of different age groups. (B) The average image quality scores pairwise comparison of different fundus diseases.

For images with clinically important findings, such as microaneurysms, neovascularization, leakage, or significant nonperfusion areas visible in the temporal peripheral retina, all observers gave the maximum score. These findings were clearly visualized, except in the low-quality image caused by retinal obstruction. The characteristics and images of representative cases are displayed in Table 3 and Figure 4, respectively.

Table 3
www.frontiersin.org

Table 3. The characteristics of representative cases.

Figure 4
Series of twelve grayscale retinal images labeled A to L, showcasing different cases numbered 1, 61, 86, 100, 157, 245, 302, 346, and 377. Each image displays various retinal patterns and vascular formations, highlighting differences in retinal conditions and abnormalities.

Figure 4. The images of representative cases. (A) Case 1: Diabetic retinopathy, neovascularization at the optic disc, non-perfusion areas. (B) Case 61: BRVO, peripheral non-perfusion area of superior temporal retina. (C,D) Case86: ROP, brush-like changes in peripheral retinal vessels in both eyes. (E) Case 100: FEVR, the peripheral retinal vessels on the nasal side of the right eye exhibited brush-like alterations and neovascularization observed clearly anterior to the crests. (F) Case 157: Uveitis, reflected fluorescence leakage from the retinal capillaries. (G,H) Case 245: Peripheral retinal degeneration, peripheral retinal degeneration areas and holes in both eyes. (I) Case 302: Central exudative chorioretinitis, macular choroidal neovascularization. (J,K) Case 346: Central serous chorioretinopathy, macular fluorescence leakage points expanded gradually. (L) Case 377: Optic neuropathy, fluorescence leakage of optic disc.

3.3 Phase wise vascular visualization following oral intake

As shown in Table 4, in the under 18 years group, the first appearance time was 3.213 ± 2.958 min, detailed visualization time was 5.804 ± 3.990 min, and optimal visualization time was 12.996 ± 8.109 min. In the 18–60 years group, these times were 3.702 ± 3.846 min, 6.100 ± 4.831 min, and 13.802 ± 7.889 min, respectively. In the over 60 years group, the times were 3.436 ± 1.861 min, 5.722 ± 2.886 min, and 14.524 ± 7.471 min, respectively. When categorized by disease, the first appearance time was 3.920 ± 3.679 min for retinal vascular diseases, 3.362 ± 3.566 min for chorioretinitis, 3.061 ± 2.162 min for retinal degenerative diseases, 4.008 ± 4.452 min for macular diseases, and 2.859 ± 1.374 min for optic nerve diseases. The detailed visualization time were 6.408 ± 4.246 min, 5.981 ± 4.337 min, 5.576 ± 4.618 min, 6.204 ± 5.327 min, and 4.956 ± 1.964 min, respectively. The optimal visualization time were 14.781 ± 8.888 min, 12.761 ± 7.738 min, 13.003 ± 6.762 min, 14.677 ± 7.997 min, and 11.973 ± 4.248 min, respectively. Whether grouped by age or disease category, there were no statistically significant differences in the recorded times among the different subgroups within each grouping category (Figure 5).

Table 4
www.frontiersin.org

Table 4. The first appearance time, detailed visualization time and optimal visualization time of different groups.

Figure 5
Three violin plots in section A show the first appearance, detailed visualization, and optimal visualization times for age groups: under 18, 18-60, and over 60 years, with some p-values indicating statistical significance. Section B has similar plots, comparing time metrics for different eye diseases: retinal vascular, chorioretinitis, retinal degenerative, macular, and optic nerve diseases. Each plot details overlapping data distributions and p-values.

Figure 5. The circulation times pairwise comparison of different groups. (A) The circulation times pairwise comparison of different age groups. (B) The circulation times pairwise comparison of different fundus diseases.

3.4 Adverse events

Six patients experienced nausea, and two patients had mild skin rash, which resolved spontaneously after about an hour. The characteristics of adverse event cases are displayed in Table 5. In other cases, including 6 patients with a history of fluorescein allergy during IVFA, there were no adverse events after oral FA. The incidence of adverse drug reactions was 2.1%.

Table 5
www.frontiersin.org

Table 5. The characteristics of adverse event cases.

4 Discussion

Fluorescein angiography (FA) is a key technique for diagnosing retinal diseases (Lv et al., 2023). However, the risk of severe allergic reactions associated with IVFA remains a significant concern in clinical practice (Occhiutto et al., 2012; Ghaleb et al., 2025). Oral FA substantially reduces this risk, yet its widespread application has long been limited by perceived poor image quality (Jiang et al., 2022; Nayak and Ghose, 1987). This study, utilizing ultra-wide-field scanning laser ophthalmoscopy and an appropriate dose of sodium fluorescein, systematically evaluated the image quality, circulation time, and safety of oral FA across different age groups and various retinal diseases. The results demonstrate that oral FA is suitable not only for children but also generates high quality, diagnostically valuable images in adult and elderly patients, serving as a safe, effective, and convenient alternative to IVFA.

Previous research on oral FA has primarily focused on pediatric populations, especially preschoolers and school-aged children (Yamao et al., 2021; Conner et al., 2023; Ling et al., 2022). This is mainly due to lower acceptance and poorer cooperation with venipuncture in children, whereas the oral route is more readily accepted by both young patients and their parents. For instance, Yamao et al. showed that oral FA combined with ultra-wide-field imaging effectively evaluated key findings such as the foveal avascular zone (FAZ) and neovascularization in children (Yamao et al., 2021). Although Hara et al. demonstrated the feasibility of oral FA in 1787 patients, systematic subgroup comparisons were not performed (Hara et al., 1998). However, these studies lacked systematic evaluation in adult and elderly populations. Our study enrolled 382 patients (676 eyes), covering a wide age range from 4 to 83 years, and performed stratified analysis based on age and disease type, addressing the shortcomings of previous studies with a single population and inadequate stratification. It not only confirmed the advantages of oral FA in children but also, for the first time, systematically compared image quality and circulation characteristics in adult and elderly patients, expanding the applicable scope of oral FA.

This study shows that high quality angiograms can be obtained with oral FA in the vast majority of cases. Overall, 374 out of 382 cases (662 out of 676 eyes) were classified as high quality. Clinically useful images were obtained in 381 cases (99.7%), with only one case yielding low-quality images due to vitreous hemorrhage. When stratified by age, no statistically significant differences were found in the average image quality scores among the different age groups (P > 0.05), suggesting that oral FA maintains stable image quality across all age ranges. This finding is important considering that earlier studies focused predominantly on pediatric populations and rarely included adults or the elderly. When grouped by disease type, all groups maintained high image quality scores, yet a statistically significant difference was observed between retinal vascular diseases and retinal degenerative diseases. This discrepancy may be related to different pathological and physiological changes in various diseases. Retinal degenerative diseases, such as retinitis pigmentosa, are primarily characterized by a progressive loss of photoreceptors and retinal pigment epithelium (RPE) (Viktoria et al., 2023; Xiaoqian et al., 2022). This often leads to attenuation of retinal vessels and widespread RPE atrophy. The subsequent reduction in both vascular density and the masking effect of the RPE may result in a clearer, higher-contrast angiographic image, as the fluorescent dye circulates through a less crowded and less obscured vascular bed. Conversely, retinal vascular diseases, including diabetic retinopathy and retinal vein occlusions, are frequently associated with pathological changes that directly impair image clarity. Media opacities such as vitreous hemorrhage, intraretinal edema, and hard exudates can scatter and attenuate the fluorescent signal. Furthermore, the presence of extensive capillary dropout or non-perfusion can reduce the overall fluorescence intensity in large areas of the retina. These factors collectively contribute to the relatively lower, though still diagnostically adequate, image quality scores in this category. Previous oral FA studies (Conner et al., 2023; Ling et al., 2022), limited primarily to children, could not perform such cross-disease comparisons. Therefore, our data provide new insights into the performance of oral FA across different patient populations.

This study also systematically recorded three key time points after oral fluorescein administration: first appearance time, detailed visualization time, and optimal visualization time. The results showed no statistically significant differences in these time points among the different age groups (P > 0.05). This indicates that even in elderly patients, the absorption and circulation of fluorescein have not shown significant delay, further supporting the feasibility of oral FA across the entire age spectrum. Among disease groups, the optic nerve diseases group had the shortest circulation times at all phases, while the retinal vascular diseases group was slightly longer, possibly related to the fact that the latter often accompanies blood circulation disorders. However, no statistical differences were reached between groups, indicating stable pharmacokinetic characteristics of oral FA across different retinal diseases.

Compared to IVFA, oral FA has several advantages. Firstly, the incidence of adverse reactions to oral FA is usually lower than that of IVFA (Garcia et al., 1999; Kelley and Kincaid, 1979; Watson and Rosen, 1990). No serious adverse events have been reported in previous oral FA studies (Barteselli et al., 2013; Kwan et al., 2006). For example, Hara et al. assessed the safety of oral FA in 1787 patients and found only 31 (1.7%) experienced minor symptoms like itching or nausea, with no severe adverse reactions observed (Kelley and Kincaid, 1979). In our study, mild adverse reactions occurred in 8 patients (2.1%), including 2 cases of mild rash and 6 cases of nausea, all of which resolved spontaneously within 1 hour. No severe allergic reactions were observed. Notably, 6 patients in this study had a history of fluorescein allergy, but no adverse reactions were observed after taking oral FA, further demonstrating the safety of oral FA. Compared to IVFA, oral FA significantly reduces the risk of allergies, especially suitable for patients with a history of allergies. Secondly, oral FA does not require needle venipuncture, making it more acceptable to patients, especially minors. In this study, all minor patients completed the oral FA and obtained high quality contrast images. Therefore, oral FA is suitable for patients who cannot tolerate venipuncture or cannot cooperate, especially pre-school and school-age children.

Despite its advantages, oral FA has certain limitations. First, it struggles to capture images of the early ocular circulation phases, such as the arterial phase. In this study, the arterial phase was absent in almost all cases. The slower rise in plasma sodium fluorescein concentration after oral administration compared to intravenous injection nearly prevents the capture of early retinal arterial perfusion. This makes oral FA less suitable for conditions requiring observation of early retinal vascular filling, such as central retinal vein occlusion. However, for most retinal diseases, including diabetic retinopathy, uveitis, and macular diseases, it provides sufficient diagnostic information. Second, the bitter taste of the sodium fluorescein solution may be difficult for some patients to tolerate, potentially preventing successful ingestion. Mixing the dye with sugar or fruit juice can help improve its taste.

This study also has several limitations. First, although the sample size is larger than in previous studies, the number of cases in certain subgroups (such as the optic nerve diseases) remains relatively small. This may limit the statistical power to detect subtle differences in image quality or circulation timing within these specific disease categories. Future studies with larger, more balanced cohorts are needed to confirm these subgroup findings. Second, while we included a broad spectrum of fundus diseases, certain rare or complex conditions may not have been sufficiently represented. Expanding the range of diseases in future investigations would help to further validate the generalizability of oral FA in diverse clinical scenarios. Third, this was a single-center study and the findings may be influenced by local patient demographics, equipment-specific factors, or institutional practices. Further multi-center studies involving diverse geographic and clinical settings would help to corroborate our results and strengthen the external validity of oral FA as a widely applicable diagnostic tool.

5 Conclusion

Oral FA is a safe, well-tolerated, and clinically effective imaging modality for evaluating retinal diseases across different age groups. Our results confirm its utility not only in children but also in adults and the elderly. The ability to obtain high quality, diagnostically adequate images without the need for intravenous access makes oral FA a promising alternative to conventional IVFA, particularly in settings where patient comfort, safety, and resource efficiency are prioritized. In summary, our study systematically validates the safety and applicability of oral FA across different ages and diseases in a large cohort, demonstrating its promise as a viable alternative to IVFA for specific populations such as pediatric, needle-phobic, or allergy-prone patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the Medical Ethics Committee of Shenzhen Ophthalmic Center. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

YJ: Writing – original draft, Investigation, Data curation. XH: Writing – original draft, Investigation, Data curation. YH: Data curation, Writing – original draft, Investigation. SL: Data curation, Writing – original draft, Investigation. XiL: Investigation, Writing – original draft, Data curation. XuL: Investigation, Data curation, Writing – original draft. ZL: Writing – original draft, Data curation, Investigation. SZ: Writing – review and editing, Project administration. WY: Project administration, Writing – review and editing. YX: Writing – review and editing, Project administration.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Shenzhen Medical Research Special Fund Project (C2401007), the National Natural Science Foundation of China (82301223), the National Natural Science Foundation of China (82271102).

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2025.1733128/full#supplementary-material

References

Ahmed, M., Syrine, B. M., Nadia, B. A., Anis, M., Karim, Z., Mohamed, G., et al. (2021). Optical coherence tomography angiography features of macular neovascularization in wet age-related macular degeneration: a cross-sectional study. Ann. Med. Surg. (Lond). 70 (0), 102826. doi:10.1016/j.amsu.2021.102826

PubMed Abstract | CrossRef Full Text | Google Scholar

Ali, S. M. A., Khan, I., Khurram, D., and Kozak, I. (2018). Ultra-widefield angiography with oral fluorescein in pediatric patients with retinal disease. JAMA Ophthalmol. 136 (5), 593–594. doi:10.1001/jamaophthalmol.2018.0462

PubMed Abstract | CrossRef Full Text | Google Scholar

Amador-Patarroyo, M. J., Lin, T., Meshi, A., Dans, K. C., Chen, K., Borooah, S., et al. (2020). Identifying the factors for improving quality of oral fluorescein angiography. Br. J. Ophthalmol. 104 (4), 504–508. doi:10.1136/bjophthalmol-2019-314187

PubMed Abstract | CrossRef Full Text | Google Scholar

Amram, A. L., Makkouk, F., Pace, S. T., Kellogg, C., and Elkeeb, A. (2018). Sublingual/transmucosal fluorescein angiography. Ophthalmol. Retina 2 (9), 980–982. doi:10.1016/j.oret.2018.04.001

PubMed Abstract | CrossRef Full Text | Google Scholar

Barteselli, G., Chhablani, J., Lee, S. N., Wang, H., El Emam, S., Kozak, I., et al. (2013). Safety and efficacy of oral fluorescein angiography in detecting macular edema in comparison with spectral-domain optical coherence tomography. Retina 33 (8), 1574–1583. doi:10.1097/IAE.0b013e318285cd84

PubMed Abstract | CrossRef Full Text | Google Scholar

Bulson, R., and Faridi, A. (2017). Normotensive glaucoma Follow-Up with incidental finding of choroidal neovascular membrane: a teaching case report. Optom. Educ. 42 (17), 16–22.

PubMed Abstract | Google Scholar

Chen, X., Zhu, W., and Li, X. (2022). OCT macular volume as a predictor of vascular leakage in uveitis. Ophthalmol. Ther. 11 (5), 1913–1924. doi:10.1007/s40123-022-00558-z

PubMed Abstract | CrossRef Full Text | Google Scholar

Conner, E. A., Eldib, A., Hiasat, J. G., Pihlblad, M. S., Errera, M. H., Chhablani, P. P., et al. (2023). Pediatric oral fluorescein angiography: a retrospective review from a single institution. J. AAPOS 27 (4), 191 e1–e6. doi:10.1016/j.jaapos.2023.06.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Ebrahimiadib, N., Hadavand Mirzaei, S., Riazi-Esfahani, H., and Amini, M. (2023). Renal function following fluorescein angiography in diabetic patients with chronic kidney disease. J. Ophthalmic Vis. Res. 18 (2), 170–174. doi:10.18502/jovr.v18i2.13183

PubMed Abstract | CrossRef Full Text | Google Scholar

Elhusseiny, A. M., Fong, J. W., Hsu, C., Grigorian, F., Grigorian, A. P., Soliman, M. K., et al. (2023). Oral fluorescein angiography for the diagnosis of papilledema versus pseudopapilledema in children. Am. J. Ophthalmol. 245 (0), 8–13. doi:10.1016/j.ajo.2022.08.020

PubMed Abstract | CrossRef Full Text | Google Scholar

Friberg, T. R., Gupta, A., Yu, J., Huang, L., Suner, I., Puliafito, C. A., et al. (2008). Ultrawide angle fluorescein angiographic imaging: a comparison to conventional digital acquisition systems. Ophthalmic Surg. Lasers Imaging 39 (4), 304–311. doi:10.3928/15428877-20080701-06

PubMed Abstract | CrossRef Full Text | Google Scholar

Fung, T. H., Muqit, M. M., Mordant, D. J., Smith, L. M., and Patel, C. K. (2014). Noncontact high-resolution ultra-wide-field oral fluorescein angiography in premature infants with retinopathy of prematurity. JAMA Ophthalmol. 132 (1), 108–110. doi:10.1001/jamaophthalmol.2013.6102

PubMed Abstract | CrossRef Full Text | Google Scholar

Garcia, C. R., Rivero, M. E., Bartsch, D. U., Ishiko, S., Takamiya, A., Fukui, K., et al. (1999). Oral fluorescein angiography with the confocal scanning laser ophthalmoscope. Ophthalmology 106 (6), 1114–1118. doi:10.1016/S0161-6420(99)90264-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Ghaleb, R., Sallam, A. B., Grigorian, F., Phillips, P. H., and Elhusseiny, A. M. (2025). Oral fluorescein angiography in pediatric ophthalmology. Surv. Ophthalmol. 70 (5), 849–858. doi:10.1016/j.survophthal.2025.03.005

PubMed Abstract | CrossRef Full Text | Google Scholar

Hans, A., Narang, S., Sindhu, M., Jain, S., and Chawla, D. (2022). Fundus fluorescein angiography in retinopathy of prematurity. Eye (Lond). 36 (8), 1604–1609. doi:10.1038/s41433-021-01694-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Hara, T., Inami, M., and Hara, T. (1998). Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein. Am. J. Ophthalmol. 126 (4), 560–564. doi:10.1016/s0002-9394(98)00112-3

PubMed Abstract | CrossRef Full Text | Google Scholar

He, J., Wang, J., Han, Z., Ma, J., Wang, C., and Qi, M. (2023). An interpretable transformer network for the retinal disease classification using optical coherence tomography. Sci. Rep. 13 (1), 3637. doi:10.1038/s41598-023-30853-z

PubMed Abstract | CrossRef Full Text | Google Scholar

Hitosugi, M., Omura, K., Yokoyama, T., Kawato, H., Motozawa, Y., Nagai, T., et al. (2004). An autopsy case of fatal anaphylactic shock following fluorescein angiography: a case report. Med. Sci. Law 44 (3), 264–265. doi:10.1258/rsmmsl.44.3.264

PubMed Abstract | CrossRef Full Text | Google Scholar

Ji, Y., Ji, Y., Liu, Y., Zhao, Y., and Zhang, L. (2023). Research progress on diagnosing retinal vascular diseases based on artificial intelligence and fundus images. Front. Cell Dev. Biol. 11 (0), 1168327. doi:10.3389/fcell.2023.1168327

PubMed Abstract | CrossRef Full Text | Google Scholar

Jiang, Z., Sun, L., Hou, A., Zhang, T., Lai, Y., Huang, L., et al. (2022). Oral fluorescein angiography with ultra-wide-field scanning laser ophthalmoscopy in pediatric patients precis: oral fluorescein angiography in children. J. Clin. Med. 11 (18), 5421. doi:10.3390/jcm11185421

PubMed Abstract | CrossRef Full Text | Google Scholar

Kelley, J. S., and Kincaid, M. (1979). Retinal fluorography using oral fluorescein. Arch. Ophthalmol. 97 (12), 2331–2332. doi:10.1001/archopht.1979.01020020547007

PubMed Abstract | CrossRef Full Text | Google Scholar

Kornblau, I. S., and El-Annan, J. F. (2019). Adverse reactions to fluorescein angiography: a comprehensive review of the literature. Surv. Ophthalmol. 64 (5), 679–693. doi:10.1016/j.survophthal.2019.02.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwan, A. S., Barry, C., McAllister, I. L., and Constable, I. (2006). Fluorescein angiography and adverse drug reactions revisited: the lions eye experience. Clin. Exp. Ophthalmol. 34 (1), 33–38. doi:10.1111/j.1442-9071.2006.01136.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, Z., Han, Y., and Yang, X. (2023). Multi-fundus diseases classification using retinal optical coherence tomography images with swin transformer V2. J. Imaging 9 (10), 203. doi:10.3390/jimaging9100203

PubMed Abstract | CrossRef Full Text | Google Scholar

Ling, X. C., Chou, H. D., Liu, L., Wang, N. K., Lai, C. C., Chen, K. J., et al. (2022). Comparison between oral and intravenous ultrawide-field fluorescein angiography in the clinical Follow-up of children with a history of retinopathy of prematurity or prematurity. Retina 42 (7), 1330–1337. doi:10.1097/IAE.0000000000003451

PubMed Abstract | CrossRef Full Text | Google Scholar

Lip, P. L., Kolli, H., and Trivedi, D. (2020). Ultra-widefield fluorescein angiographic patterns, retinal microvascular anomalies and retinal ischemic index in branch retinal vein occlusions with established retinal neovascularization. Clin. Ophthalmol. 14 (0), 2965–2974. doi:10.2147/OPTH.S272064

PubMed Abstract | CrossRef Full Text | Google Scholar

Lv, M., Li, T., and Li, Y. (2023). Clinical application of optical coherence tomography angiography in diabetic macular edema. Afr. Health Sci. 23 (2), 484–489. doi:10.4314/ahs.v23i2.56

PubMed Abstract | CrossRef Full Text | Google Scholar

Manivannan, A., Plskova, J., Farrow, A., McKay, S., Sharp, P. F., and Forrester, J. V. (2005). Ultra-wide-field fluorescein angiography of the ocular fundus. Am. J. Ophthalmol. 140 (3), 525–527. doi:10.1016/j.ajo.2005.02.055

PubMed Abstract | CrossRef Full Text | Google Scholar

Manoharan, N., Pecen, P. E., Cherof, A. M., Oliver, S. C. N., and Palestine, A. G. (2017). Comparison of oral Versus intravenous fluorescein widefield angiography in ambulatory pediatric patients. J. Vitreoretin. Dis. 1 (3), 191–196. doi:10.1177/2474126417705256

CrossRef Full Text | Google Scholar

Marmoy, O. R., Henderson, R. H., and Ooi, K. (2022). Recommended protocol for performing oral fundus fluorescein angiography (FFA) in children. Eye (Lond). 36 (1), 234–236. doi:10.1038/s41433-020-01328-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Marziali, E., Testi, I., MacPhee, B., Ibanez, P., Allen, M., Dahlmann-Noor, A., et al. (2022). A prospective evaluation of adverse events occurring in children undergoing fundus fluorescein and indocyanine green angiography. Eye (Lond). 36 (9), 1837–1839. doi:10.1038/s41433-022-01951-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Nayak, B. K., and Ghose, S. (1987). A method for fundus evaluation in children with oral fluorescein. Br. J. Ophthalmol. 71 (12), 907–909. doi:10.1136/bjo.71.12.907

PubMed Abstract | CrossRef Full Text | Google Scholar

Noh, M., Kim, Y., Zhang, H., Kim, H., Bae, C. R., Lee, S., et al. (2023). Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases. Eur. J. Pharmacol. 939 (0), 175427. doi:10.1016/j.ejphar.2022.175427

PubMed Abstract | CrossRef Full Text | Google Scholar

Occhiutto, M. L., Freitas, F. R., Maranhao, R. C., and Costa, V. P. (2012). Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics 4 (2), 252–275. doi:10.3390/pharmaceutics4020252

PubMed Abstract | CrossRef Full Text | Google Scholar

Sawyer, C., Huang, L. C., Vincent, J., Cabrera, M. T., Herlihy, E., and Mustafi, D. (2024). Diagnostic role of oral fluorescein angiography in pediatric ambulatory clinics. Ophthalmol. Retina 8 (2), 204–206. doi:10.1016/j.oret.2023.10.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Squirrell, D., Dinakaran, S., Dhingra, S., Mody, C., Brand, C., and Talbot, J. (2005). Oral fluorescein angiography with the scanning laser ophthalmoscope in diabetic retinopathy: a case controlled comparison with intravenous fluorescein angiography. Eye (Lond). 19 (4), 411–417. doi:10.1038/sj.eye.6701513

PubMed Abstract | CrossRef Full Text | Google Scholar

Su, Z., Ye, P., Teng, Y., Zhang, L., and Shu, X. (2012). Adverse reaction in patients with drug allergy history after simultaneous intravenous fundus fluorescein angiography and indocyanine green angiography. J. Ocul. Pharmacol. Ther. 28 (4), 410–413. doi:10.1089/jop.2011.0221

PubMed Abstract | CrossRef Full Text | Google Scholar

Sugimoto, M., Matsubara, H., Miyata, R., Matsui, Y., Ichio, A., and Kondo, M. (2014). Ultra-WideField fluorescein angiography by oral administration of fluorescein. Acta Ophthalmol. 92 (5), e417–e418. doi:10.1111/aos.12323

PubMed Abstract | CrossRef Full Text | Google Scholar

Temkar, S., Azad, S. V., Chawla, R., Damodaran, S., Garg, G., Regani, H., et al. (2019). Ultra-widefield fundus fluorescein angiography in pediatric retinal vascular diseases. Indian J. Ophthalmol. 67 (6), 788–794. doi:10.4103/ijo.IJO_1688_18

PubMed Abstract | CrossRef Full Text | Google Scholar

Tsui, I., Bajwa, A., Franco-Cardenas, V., Pan, C. K., Kim, H. Y., and Schwartz, S. D. (2013). Peripheral fluorescein angiographic findings in fellow eyes of patients with branch retinal vein occlusion. Int. J. Inflam. 2013 (0), 464127. doi:10.1155/2013/464127

PubMed Abstract | CrossRef Full Text | Google Scholar

Viktoria, D., Akos, L., Gergely, S., Rovena, S., Adrienn, M., Andrea, K.-V., et al. (2023). Long-term effects of the pituitary-adenylate cyclase-activating polypeptide (PACAP38) in the adult mouse retina: microglial activation and induction of neural proliferation. Neurochem. Res. 48 (11), 3430–3446. doi:10.1007/s11064-023-03989-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Watson, A. P., and Rosen, E. S. (1990). Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules. Br. J. Ophthalmol. 74 (8), 458–461. doi:10.1136/bjo.74.8.458

PubMed Abstract | CrossRef Full Text | Google Scholar

Xiaoqian, D., Ryan, L., Sin Yee, L., Zheng, Z., Jing, W., Yizhi, L., et al. (2022). Global transcriptional and epigenetic reconfiguration during chemical reprogramming of human retinal pigment epithelial cells into photoreceptor-like cells. Cells 11 (19), 3146. doi:10.3390/cells11193146

PubMed Abstract | CrossRef Full Text | Google Scholar

Yamao, S., Tsujioka, T., Takada, R., Matsumoto, F., and Kusaka, S. (2021). Utility of oral fluorescein angiography with ultra-widefield imaging system for evaluation of various retinal disorders. Retina 41 (6), 1338–1345. doi:10.1097/IAE.0000000000003011

PubMed Abstract | CrossRef Full Text | Google Scholar

Yu, T., Shao, A., Wu, H., Su, Z., Shen, W., Zhou, J., et al. (2025). A systematic review of advances in AI-Assisted analysis of fundus fluorescein Angiography (FFA) images: from detection to report generation. Ophthalmol. Ther. 14 (4), 599–619. doi:10.1007/s40123-025-01109-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: fluorescein angiography, fundus diseases, intravenous FA, oral FA, ultra-wide-field imaging

Citation: Ji Y, Hu X, Hu Y, Lai S, Lu X, Li X, Liu Z, Zhang S, Yang W and Yao X (2026) Orally administered fluorescein angiography for ultra-wide-field imaging: is a safe and effective modality across different age groups and fundus diseases?. Front. Cell Dev. Biol. 13:1733128. doi: 10.3389/fcell.2025.1733128

Received: 27 October 2025; Accepted: 15 December 2025;
Published: 08 January 2026.

Edited by:

Guang-Yu Li, Jilin University, China

Reviewed by:

Jingyuan Yang, Peking Union Medical College Hospital (CAMS), China
Li Li, The University of Melbourne, Australia

Copyright © 2026 Ji, Hu, Hu, Lai, Lu, Li, Liu, Zhang, Yang and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xue Yao, MTg5MjUyNTcxMjFAMTYzLmNvbQ==; Weihua Yang, YmVuYmVuMDYwNkAxMzkuY29t; Shaochong Zhang, U2hhb2Nob25nemhhbmdAb3V0bG9vay5jb20=

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.